EP0868196A4 - Synthetischer impfstoff zum schutz gegen eine infektion durch das humane immundefizienz virus - Google Patents

Synthetischer impfstoff zum schutz gegen eine infektion durch das humane immundefizienz virus

Info

Publication number
EP0868196A4
EP0868196A4 EP96936830A EP96936830A EP0868196A4 EP 0868196 A4 EP0868196 A4 EP 0868196A4 EP 96936830 A EP96936830 A EP 96936830A EP 96936830 A EP96936830 A EP 96936830A EP 0868196 A4 EP0868196 A4 EP 0868196A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
synthesis
protection against
immunodeficiency virus
virus infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96936830A
Other languages
English (en)
French (fr)
Other versions
EP0868196A1 (de
Inventor
Barton F Haynes
Thomas J Palker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/546,515 external-priority patent/US5993819A/en
Application filed by Duke University filed Critical Duke University
Publication of EP0868196A1 publication Critical patent/EP0868196A1/de
Publication of EP0868196A4 publication Critical patent/EP0868196A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP96936830A 1995-10-20 1996-10-18 Synthetischer impfstoff zum schutz gegen eine infektion durch das humane immundefizienz virus Withdrawn EP0868196A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US546515 1995-10-20
US08/546,515 US5993819A (en) 1987-09-08 1995-10-20 Synthetic vaccine for protection against human immunodeficiency virus infection
US59926696A 1996-02-09 1996-02-09
US599266 1996-02-09
PCT/US1996/016911 WO1997014436A1 (en) 1995-10-20 1996-10-18 Synthetic vaccine for protection against human immunodeficiency virus infection

Publications (2)

Publication Number Publication Date
EP0868196A1 EP0868196A1 (de) 1998-10-07
EP0868196A4 true EP0868196A4 (de) 2004-11-24

Family

ID=27068273

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96936830A Withdrawn EP0868196A4 (de) 1995-10-20 1996-10-18 Synthetischer impfstoff zum schutz gegen eine infektion durch das humane immundefizienz virus

Country Status (5)

Country Link
EP (1) EP0868196A4 (de)
JP (1) JPH11515006A (de)
AU (1) AU7465696A (de)
CA (1) CA2235168A1 (de)
WO (1) WO1997014436A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814925C2 (de) * 1998-04-03 2000-10-05 Thomas Harrer Arzneimittel zur Induktion zytotoxischer T-Zellen
JP2004503205A (ja) * 2000-02-04 2004-02-05 デューク・ユニバーシティー ヒト免疫不全ウイルスワクチン
JP2004511444A (ja) 2000-09-22 2004-04-15 デューク・ユニバーシティー 免疫原
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
WO2003039470A2 (en) 2001-11-07 2003-05-15 Duke University Polyvalent immunogen of hiv
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
WO2008133652A2 (en) * 2006-11-09 2008-11-06 Sudhir Paul Binary epitope antibodies and b cell superantigen immune stimulants
US7892562B2 (en) 2008-10-08 2011-02-22 Karp Nelson M Methods of inducing TH-1 immune responses to HIV-1 by administering UV/psoralen-treated desialated inactiviated HIV-1 virions deficient in CD55 and CD59
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227169A2 (de) * 1985-12-17 1987-07-01 Akzo N.V. Immunochemisches Reagenz
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
EP0387914A1 (de) * 1984-10-18 1990-09-19 Institut Pasteur Hüllenantigene vom menschlichen Immunodefizienz-Virus und deren Verwendungen
WO1995029700A1 (en) * 1994-04-29 1995-11-09 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387914A1 (de) * 1984-10-18 1990-09-19 Institut Pasteur Hüllenantigene vom menschlichen Immunodefizienz-Virus und deren Verwendungen
EP0227169A2 (de) * 1985-12-17 1987-07-01 Akzo N.V. Immunochemisches Reagenz
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
WO1995029700A1 (en) * 1994-04-29 1995-11-09 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GROENINK M ET AL: "PHENOTYPE-ASSOCIATE ENV GENE VARIATION AMONG EIGHT RELATED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CLONES: EVIDENCE FOR IN VIVO RECOMBINATION AND DETERMINANTS OF CYTOTROPISM OUTSIDE THE V3 DOMAIN", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 10, October 1992 (1992-10-01), pages 6175 - 6180, XP009019329, ISSN: 0022-538X *
LOPALCO L ET AL: "IDENTIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 GLYCOPROTEIN GP120/GP41 INTERACTION SITES BY THE IDIOTYPIC MIMICRY OF TWO MONOCLONAL ANTIBODIES", AIDS RESEARCH AND HUMAN RETROVIRUSES, NEW YORK, NY, US, vol. 9, no. 1, January 1993 (1993-01-01), pages 33 - 39, XP001059095, ISSN: 0889-2229 *
NEURATH A R ET AL: "SYNTHETIC PEPTIDES AND ANTI-PEPTIDE ANTIBODIES AS PROBES TO STUDY INTERDOMAIN INTERACTIONS INVOLVED IN VIRUS ASSEMBLY THE ENVELOPE OF THE HUMAN IMMUNODEFICIENCY VIRUS HIV-1", VIROLOGY, vol. 188, no. 1, 1992, pages 1 - 13, XP008035866, ISSN: 0042-6822 *
PALKER T ET AL: "Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 142, no. 10, 15 May 1989 (1989-05-15), pages 3612 - 3619, XP002158688, ISSN: 0022-1767 *
See also references of WO9714436A1 *
STAMAMTATOS LEONIDAS ET AL: "Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1", JOURNAL OF VIROLOGY, vol. 68, no. 8, 1994, pages 4973 - 4979, XP002297224, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO1997014436A1 (en) 1997-04-24
AU7465696A (en) 1997-05-07
EP0868196A1 (de) 1998-10-07
CA2235168A1 (en) 1997-04-24
JPH11515006A (ja) 1999-12-21

Similar Documents

Publication Publication Date Title
EP0676954A4 (de) Hiv-lockvirus.
SI0831921T1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
BR9007917A (pt) Vacina aperfeicoada de conjugado polissacaridico meningogocico
EP0868403A4 (de) Synthese von "312" phasen und zusammensetzungen davon
EP0868196A4 (de) Synthetischer impfstoff zum schutz gegen eine infektion durch das humane immundefizienz virus
LTIP335A (en) Vaccine for human immunodeficiency virus
EP1670507A4 (de) Vakzine zur behandlung und prävention von herpes simplex-virusinfektion
FI944052A0 (fi) Oraalinen rokote
EP1120118A4 (de) Präventiva/mittel für infektion, anti-endotoxin mittel, impfstoff-adjuvanzien sowie wachstumspromotoren
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
NZ310055A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
AU1463992A (en) Methods and pharmaceutical compositions for inhibiting protease from human immunodeficiency virus
IL94558A0 (en) Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
AU7677891A (en) Inhibition of disease associated with immunodeficiency virus infection
IL114501A (en) Marek's disease virus vaccine
ZA96722B (en) Combination therapy for hiv infection
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
EP0769952A4 (de) Impfstoff gegen das infektiöse hühneranämie-virus
IT1289238B1 (it) Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus
EP0963441A4 (de) Inaktivierung von hiv ko-rezeptoren zur therapie der hiv-infektion
FI965196L (fi) HIV-infektion yhdistelmähoito
AU5398296A (en) Vaccine for the immunoprophylaxis of the infection from feli ne immunodeficiency virus in the domestic cat
IT1277117B1 (it) Composizioni farmaceutiche per il trattamento delle ipercolesterolemie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/16 B

Ipc: 7A 61K 38/16 B

Ipc: 7G 01N 33/567 B

Ipc: 7G 01N 33/53 B

Ipc: 7C 12Q 1/70 B

Ipc: 7A 61K 38/04 B

Ipc: 7A 61K 38/00 B

Ipc: 7A 61K 39/21 A

A4 Supplementary search report drawn up and despatched

Effective date: 20041011

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041224